311 related articles for article (PubMed ID: 17765191)
1. Non-[18F]FDG PET in clinical oncology.
Groves AM; Win T; Haim SB; Ell PJ
Lancet Oncol; 2007 Sep; 8(9):822-30. PubMed ID: 17765191
[TBL] [Abstract][Full Text] [Related]
2. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
3. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
4. Clinical PET in oncology: not only FDG.
Nanni C; Rubello D; Al-Nahhas A; Fanti S
Nucl Med Commun; 2006 Sep; 27(9):685-8. PubMed ID: 16894321
[No Abstract] [Full Text] [Related]
5. Standardization and quantification in PET/CT imaging: tracers beyond FDG.
Antunovic L; Rodari M; Rossi P; Chiti A
PET Clin; 2014 Jul; 9(3):259-66. PubMed ID: 25030389
[TBL] [Abstract][Full Text] [Related]
6. The role of 18F-FDG PET in oncology: clinical and resource implications.
Al-Nahhas A; Win Z; Singh A; Khan S; Al-Sayed Y
Nucl Med Rev Cent East Eur; 2006; 9(1):1-5. PubMed ID: 16791796
[No Abstract] [Full Text] [Related]
7. PET tracers in musculoskeletal disease beyond FDG.
Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
[TBL] [Abstract][Full Text] [Related]
8. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases.
Pantaleo MA; Nannini M; Lopci E; Castellucci P; Maleddu A; Lodi F; Nanni C; Allegri V; Astorino M; Brandi G; Di Battista M; Boschi S; Fanti S; Biasco G
Int J Oncol; 2008 Sep; 33(3):443-52. PubMed ID: 18695872
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging: what can be used today.
Jager PL; de Korte MA; Lub-de Hooge MN; van Waarde A; Koopmans KP; Perik PJ; de Vries EG
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S27-32. PubMed ID: 16361133
[TBL] [Abstract][Full Text] [Related]
11. Advances in metabolic imaging for surgical oncology.
Iagaru A; Quon A
Surg Oncol Clin N Am; 2007 Apr; 16(2):273-92. PubMed ID: 17560512
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
13. Clinical molecular imaging with positron emission tomography.
Saleem A; Charnley N; Price P
Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
[TBL] [Abstract][Full Text] [Related]
14. The next generation of positron emission tomography radiopharmaceuticals in oncology.
Rice SL; Roney CA; Daumar P; Lewis JS
Semin Nucl Med; 2011 Jul; 41(4):265-82. PubMed ID: 21624561
[TBL] [Abstract][Full Text] [Related]
15. Molecular imaging using PET for breast cancer.
Kurihara H; Shimizu C; Miyakita Y; Yoshida M; Hamada A; Kanayama Y; Yonemori K; Hashimoto J; Tani H; Kodaira M; Yunokawa M; Yamamoto H; Watanabe Y; Fujiwara Y; Tamura K
Breast Cancer; 2016 Jan; 23(1):24-32. PubMed ID: 25917108
[TBL] [Abstract][Full Text] [Related]
16. PET imaging of brain tumors.
Fischman AJ
Cancer Treat Res; 2008; 143():67-92. PubMed ID: 18619214
[No Abstract] [Full Text] [Related]
17. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
[TBL] [Abstract][Full Text] [Related]
18. [The contribution of PET to radiation treatment planning].
Belkacémi Y; Lartigau E; Kerrou K; Carpentier P; Taïeb S; Giraud P
Bull Cancer; 2007 Jan; 94(1):99-108. PubMed ID: 17237010
[TBL] [Abstract][Full Text] [Related]
19. Pitfall of (18)F-FDG-PET imaging in oncology: uterine fibromyoma.
Tripathi M; Khurana A; D'Souza MM; Sharma R
Hell J Nucl Med; 2009; 12(2):175-6. PubMed ID: 19675878
[No Abstract] [Full Text] [Related]
20. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
Shiue CY; Welch MJ
Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
